Solentim Appoints New Non-Executive Director
Solentim are pleased to announce the appointment of Dr Julian Burke as a non-executive Director. A former lecturer in Biochemistry at the University of Sussex, UK, Dr Burke has over 25 years’ experience of executive leadership positions in life science companies. He was Chief Scientific Officer for Genetix Group PLC from 2000 – 2010 until their acquisition by Danaher Corporation. From 2011 Dr Burke held executive positions within the Danaher companies, Molecular Devices, Leica Microsystems and Leica Biosystems. From 2018 he was Chief Scientific Officer and Vice President New Ventures for Danaher Corporation responsible for identifying new investment opportunities in Life Science and Diagnostics.
Dr Mark Truesdale, CEO, Solentim said, ‘We welcome Dr Burke to our board of directors. Julian’s experience and expertise in the global life sciences market will help support and accelerate our growth strategy.’
Dr Burke commented, “I am very excited for the future of Solentim in the area of single cell biology and cell therapy. This rapidly growing field has important implications for modern therapeutic applications and disease modelling.”
Sign up to our newsletter...
Keep updated on out latest product news, events, webinars and regular updates